Soluble Trem2 is a negative regulator of erythrophagocytosis after intracerebral hemorrhage in a CD36 receptor recycling manner

J Adv Res. 2023 Feb:44:185-199. doi: 10.1016/j.jare.2022.03.011. Epub 2022 Mar 18.

Abstract

Introduction: Microglia and macrophages participate in hematoma clearance after intracerebral hemorrhage (ICH), thereby facilitating tissue restoration and neurological recovery. Triggering receptor expressed on myeloid cells 2 (Trem2) has been indicated as a major pathology-induced immune signaling hub on the microglial/macrophage surface. Soluble Trem2 (sTrem2), the proteolytic form of Trem2, is abundant in the body fluid and is positively correlated with the pathological process.

Objectives: In the present study, we aimed to investigate the potential role of sTrem2 in hematoma resolution after ICH and to elucidate its underlying mechanisms.

Methods: We explored the biological functions of sTrem2 in the murine ICH brain by stereotaxic injection of recombinant sTrem2 protein or by adeno-associated virus-mediated expression. Erythrocyte phagocytosis was assessed using flow cytometry and immunofluorescence. Western blotting was performed to evaluate protein expression. Changes in behavior, sTrem2-induced down-stream pathway, and microglia were examined.

Results: sTrem2 impedes hematoma resolution and impairs functional motor and sensory recovery. Interestingly, sTrem2 bypasses full-length Trem2, negatively regulating microglial/macrophage erythrophagocytosis, and promotes an inflammatory phenotype, which is associated with reduced retromer levels and impaired recycling of the pro-erythrophagocytic receptor CD36. Rescue of retromer Vps35 abolishes the phagocytosis-inhibiting effects and lysosome-dependent CD36 degradation caused by sTrem2.

Conclusion: These findings indicate sTrem2 as a negative factor against microglia/macrophage-mediated hematoma and related neuronal damage clearance, provide insight into the mechanisms by which erythrophagocytosis is regulated and how it may be impaired after ICH, and suggest that the anti-proteolytic activity of Trem2 can be explored for ICH therapy.

Keywords: CD36 receptor recycling; Intracerebral hemorrhage; Microglia; Phagocytosis; Soluble Trem2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cerebral Hemorrhage* / complications
  • Cerebral Hemorrhage* / metabolism
  • Cerebral Hemorrhage* / pathology
  • Hematoma / complications
  • Hematoma / metabolism
  • Lymphohistiocytosis, Hemophagocytic* / complications
  • Lymphohistiocytosis, Hemophagocytic* / metabolism
  • Lymphohistiocytosis, Hemophagocytic* / pathology
  • Macrophages / metabolism
  • Membrane Glycoproteins / metabolism
  • Membrane Glycoproteins / pharmacology
  • Mice
  • Microglia / metabolism
  • Microglia / pathology
  • Phagocytosis / physiology
  • Receptors, Immunologic / metabolism
  • Vesicular Transport Proteins / metabolism
  • Vesicular Transport Proteins / pharmacology

Substances

  • Vps35 protein, mouse
  • Vesicular Transport Proteins
  • Trem2 protein, mouse
  • Membrane Glycoproteins
  • Receptors, Immunologic